XOMA CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.27 USD | 0.00% |
|
+0.16% | +0.60% |
| 06-12 | XOMA Receives $8.1 Million Milestone Related to Sale of Priority Review Voucher | MT |
| 05-09 | Earnings Flash (XOMA) XOMA CORPORATION Reports Q1 Revenue $1.5M | MT |
| Sales 2024 * | 21M 28.68M | Sales 2025 * | 26.93M 36.78M | Capitalization | 285M 390M |
|---|---|---|---|---|---|
| Net income 2024 * | -22M -30.04M | Net income 2025 * | -15M -20.48M | EV / Sales 2024 * | 13.6 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 10.6 x |
| P/E ratio 2024 * |
-13
x | P/E ratio 2025 * |
-18.6
x | Employees | 13 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.47% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 week | +0.16% | ||
| Current month | +0.76% | ||
| 1 month | +0.68% | ||
| 3 months | +0.84% | ||
| 6 months | +0.54% | ||
| Current year | +0.60% |
1 week
25.17
25.34
1 month
24.9025.40
Current year
23.5025.85
1 year
20.4325.85
3 years
20.4327.95
5 years
20.4327.95
10 years
20.4327.95
| Managers | Title | Age | Since |
|---|---|---|---|
Owen Hughes
CEO | Chief Executive Officer | 49 | 22-12-31 |
Thomas Burns
DFI | Director of Finance/CFO | 50 | 06-08-13 |
Bradley Sitko
CIO | Chief Investment Officer | 43 | 23-01-02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Heather Franklin
BRD | Director/Board Member | 58 | 21-08-05 |
| Chairman | 68 | 10-08-25 | |
Joseph Limber
BRD | Director/Board Member | 71 | 12-12-11 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-25 | 25.27 | 0.00% | 2,040 |
| 24-06-24 | 25.27 | +0.08% | 2,236 |
| 24-06-21 | 25.25 | +0.07% | 2,032 |
| 24-06-20 | 25.23 | 0.00% | 3,517 |
| 24-06-18 | 25.23 | +0.04% | 2,106 |
Delayed Quote Nasdaq, June 25, 2024 at 04:30 pm
More quotes
XOMA Corporation is a biotechnology royalty aggregator. The Companyâs royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Its royalty portfolio includes DAY101 (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, TAK-079 (mezagitamab), BAY-1213790 (osocimab), AFM13 (acimtamig), AB023 (gruticibart), AB002 (E-WE thrombin), AB054, AV-299 (ficlatuzumab), COM902, vosaroxin, aldoxorubicin, INCAGN2385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, G03-52-01, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], VABYSMO (faricimab-svoa), CMP-001 (vidutolimod), and CFZ533 (iscalimab).
Calendar
2024-08-05
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
24.52
USD
Average target price
58
USD
Spread / Average Target
+136.54%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +16.45% | 123B | |
| +21.96% | 115B | |
| +23.73% | 25.85B | |
| -20.05% | 20.9B | |
| -16.28% | 16.77B | |
| -16.52% | 16.52B | |
| -44.35% | 15.56B | |
| +63.91% | 15.49B | |
| +2.52% | 13.45B |
- Stock Market
- Equities
- XOMA Stock
- XOMAO Stock
